Fanapt® (iloperidone)

Fanapt® is an atypical antipsychotic approved for the treatment of schizophrenia in adults. Fanapt® is a serotonin (5-HT2) receptor and dopamine receptor antagonist.

Under an agreement with Vanda, Novartis has development and commercial rights to Fanapt® in the US and Canada. Fanapt® was granted US Market Approval by the FDA in May 2009. In addition, Vanda currently has Fanapt® distribution partnerships in Israel and Mexico. In 2012, Fanapt® was approved for marketing in Israel and Argentina.

For U.S. full prescribing information, including box warnings and safety information, please visit


Spacers   Spacers
Home | About Vanda | Product Pipeline | Partnering | Investor Relations | News | Careers | Contact Us
Copyright © 2016 Vanda Pharmaceuticals | Terms & Conditions | Privacy Policy